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Resistant TB Is a Serious Threat to 
Global Health
Tuberculosis (TB) remains the 
leading cause of death from a largely 
preventable and curable infectious 
disease, with an estimated 1.7 million 
deaths in 2006 [1]. Global prospects 
for TB control are challenged by the 
emergence of drug-resistant strains, 
especially those that are multidrug 
resistant (MDR) and extensively drug 
resistant (XDR) [2].
Soon after anti-TB drugs became 
available in the 1940s came reports 
of drug resistance among patients 
undergoing treatment [3]. With the 
advent of “short course chemotherapy” 
in the 1980s, the duration of treatment 
fell from 24 to six months, but even 
then full adherence to treatment 
regimens has been difficult to 
accomplish, due to the extensive length 
of therapy necessary to achieve cure. 
The prevalence of TB resistant to a 
single drug was continuously on the 
rise in several parts of the world, and 
eventually in the early 1990s, multiple 
converging factors led to an explosive 
emergence of MDR-TB, defined as 
resistance to the two most effective 
first-line anti-TB agents, isoniazid and 
rifampicin.
The most recent estimates on the 
prevalence of anti-TB drug resistance 
come from surveys conducted by 
the World Health Organization and 
the International Union Against 
Tuberculosis and Lung Disease. These 
organizations investigated both new 
and previously treated TB cases in 
93 geographical settings between 
2002–2006 [4]. In these surveys, the 
prevalence of MDR-TB ranged from 
0% to 22% among newly diagnosed 
cases and from 0% to 60% among 
previously treated cases. In addition, 
since 2002, 45 countries have reported 
cases of XDR-TB, i.e., TB that is 
resistant not only to isoniazid and 
rifampicin but also to at least one 
fluoroquinolone and to any of the 
following injectable second-line drugs: 
kanamycin, amikacin, or capreomycin. 
Of the MDR isolates tested for second-
line drugs, 0%–30 % were found to be 
XDR [4].
Identification of Drug Resistance 
Mutations in TB
Drug resistance in TB is believed to be 
mediated exclusively by chromosomal 
mutations, which affect either the 
drug target itself or bacterial enzymes 
that activate prodrugs. Since the 
early 1990s, numerous studies have 
described the genetic mechanisms 
of drug resistance in Mycobacterium
tuberculosis, and a wealth of data has 
accumulated on the mutations found 
in isolates resistant to specific drugs 
[5]. For some drugs, like isoniazid 
and rifampicin, a large number of 
mutations have been identified that 
confer resistance, and these mutations 
account for most of the resistance 
found among clinical isolates. For 
other drugs, such as streptomycin and 
many of the second-line drugs, known 
drug resistance mutations occur in only 
a small proportion of resistant isolates 
[5]. As resistance has become even 
more prevalent, and high-throughput 
sequencing methods and genotyping 
strategies have been developed and 
refined, large-scale studies to identify 
the mutations associated with resistance 
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resistant TB threatens global TB control 
efforts.
sÈ 4HEREÈISÈANÈURGENTÈNEEDÈFORÈNEWÈ
diagnostic tests that rapidly identify 
drug sensitivity profiles of M.
tuberculosis strains and for new drugs 
to treat resistant disease.
sÈ 7EÈHAVEÈESTABLISHEDÈAÈCOMPREHENSIVEÈ
database listing mutations associated 
with TB drug resistance and the 
frequency of the most common 
mutations associated with resistance 
to specific drugs.
sÈ 7EÈHAVEÈMADEÈTHISÈINTERACTIVEÈ
database publicly available on the Web 
site http://www.tbdreamdb.com/ so 
that it can serve as a resource for the 
development of molecular diagnostics 
for TB.
sÈ /THERÈUSESÈOFÈTHEÈDATABASEÈINCLUDEÈ
structural mapping of mutations to 
study mechanisms of resistance for 
drug discovery purposes.
The Health in Action section is a forum for individuals 
or organizations to highlight their innovative 
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have been undertaken throughout 
the world. Until now, there has been 
no single resource where such drug 
resistance mutation data are readily 
available to use in research and 
development. In order to propel the 
use of the data that are scattered over 
a large number of publications, many 
of which are not readily accessible to 
researchers around the globe, we have 
compiled the data available on drug 
resistance mutations in M. tuberculosis
in an open-access database that can be 
used for a diverse array of purposes.
Applications of the Database
Centralized databases, curated from 
the literature or high-throughput 
experiments [6,7], have helped usher 
in the era of systems biology [8], 
and have helped researchers identify 
global trends and important biological 
features that would have only been 
apparent through a comprehensive 
analysis of the combined data [9]. 
Examples include protein–protein 
interaction databases [10,11], genomic 
databases [12,13], and microarray 
databases [14–16]. Through this 
project we present a new database 
devoted to drug resistance mutations 
in TB, called the TB Drug Resistance 
Mutation Database (TBDReaMDB). 
By providing a comprehensive, 
single resource of drug resistance 
mutations in TB, we hope to accelerate 
and encourage new discoveries 
that will have applications ranging 
from diagnostics to drug discovery. 
We envision that this database will 
expand as additional mutations are 
identified in the coming years and 
will serve as a platform for diverse 
analyses and projects. TBDReaMDB 
also complements other TB-related 
databases such as TBDB (http://www.
tbdb.org/), a recently developed Web-
based resource housing both annotated 
genome sequence data and expression 
data from M. tuberculosis and related 
species [17].
Resource for sequencing projects. 
The creation of this database was 
originally precipitated by our in-
house need for information on known 
mutations found in drug-resistant 
TB, to be used in a large-scale whole-
genome sequencing project of MDR- 
and XDR-TB strains [18]. Whole-
genome sequencing identifies a large 
number of mutations among isolates 
from diverse geographic regions 
that exhibit varying degrees of drug 
resistance. The data in the mutation 
database can be used to screen the 
mutations discovered by sequencing, 
thereby allowing the user to distinguish 
mutations and genes that previously 
have been associated with resistance 
from newly identified resistance-
associated mutations, or random 
mutations that serve as markers of the 
genetic lineage of the particular strain. 
Development of diagnostics. New
tools for rapid and accurate diagnosis 
of drug-resistant TB are urgently 
needed. Sequence-based diagnostic 
methods have been developed that 
detect specific mutations associated 
with drug resistance. These tools have 
the advantage of being rapid, high-
throughput, and easily compared 
between laboratories. However, the 
development of such diagnostic 
tools relies on detailed information 
about the mutations that lead to drug 
resistance and their relative frequency. 
Currently the two main diagnostic 
tests available commercially are the 
INNO-LiPA TB test (Innogenetics) 
[19] and the GenoType MTBDRplus
kit (Hain Lifescience) [20]. These 
assays have recently been approved by 
the World Health Organization as a 
tool for rapid MDR-TB diagnosis [21]. 
These “line probe assays” are based 
on the detection of a set number of 
mutations in a few genes associated 
with resistance against isoniazid and 
rifampicin. These assays may therefore 
be unable to detect all isoniazid and 
rifampicin resistance and do not detect 
resistance to other first-line or second-
line drugs. This database project 
establishes a foundation that we hope 
will spur future development of assays 
with improved sensitivity and specificity 
and the expansion of these tools to 
detect resistance to other first- and 
second-line drugs. In addition, the data 
may also be used in future research to 
understand the clinical importance of 
rare mutations. 
Geographical distribution and 
surveillance of mutations. Differences
in the type and frequency of mutations 
in drug-resistant isolates in diverse 
geographical regions can pose 
challenges for the development of a 
sequence-based diagnostic, especially 
if the test relies on detecting a limited 
number of mutations. Different drugs 
of the same drug class may also interact 
differently with the molecular drug 
targets and thus affect the mutations 
selected for [22,23]. In addition, some 
specific mutations have been shown 
to lead to high-level resistance, while 
others confer low-level resistance to 
a specific drug [24]. Others may lead 
to cross-resistance to drug analogs 
[25]. Regional differences in drug 
analogs used have been shown to 
select for different drug resistance 
mutations; for example, mutations 
found in regions that use specific 
rifamycin analogs differ from those 
in which other analogs are used [26]. 
The mutations that arise from these 
different drug analog exposures may 
help explain some of the reported 
geographical differences in drug 
efficacy [26]. We have therefore 
included the geographic sites of 
resistance studies in our database. 
As more data on the frequency of 
mutations become available through 
large-scale sequencing projects, we will 
garner an even more comprehensive 
understanding of the global 
distribution of specific mutations 
and a better perception of the role of 
geographical differences.
Drug discovery. The database can 
also be used for novel computational 
technologies in drug discovery. 
Mutations may be mapped onto 
protein structures in order to better 
understand the mechanisms of 
resistance at the molecular and atomic 
level. Such analyses may help us to 
better understand how particular 
mutations lead to resistance, how 
mutations impact the affinity or 
activation of corresponding drugs, 
and how mutations may impact the 
fitness of the bacteria. Trends, such 
as correlated or synergistic mutations, 
may also become apparent through the 
comprehensive analysis of the data on 
mutations associated with resistance. In 
addition to revealing the mechanisms 
of resistance on a global scale, the 
resulting mapping of mutations 
may also suggest drug modifications 
or alternative strategies to counter 
emerging drug resistance in TB.
A New Comprehensive Database
TBDReaMDB is a comprehensive 
resource on drug resistance mutations 
in M. tuberculosis. We conducted a 
systematic review (see Text S1 for a 
brief description of the systematic 
review strategy) to identify drug 
resistance mutations from the existing PLoS Medicine  |  www.plosmedicine.org 0134 February 2009  |  Volume 6  |  Issue 2  |  e1000002
literature to include in the database. 
We chose not to make any a priori 
decisions as to whether the mutations 
described in the literature actually 
confer drug resistance or are possible 
secondary compensatory mutations, 
but instead included all mutations 
that have been described in drug-
resistant strains more often than drug-
sensitive isolates. For each mutation, 
the database provides complete codon 
changes for each mutation at both the 
nucleotide and amino acid level.
Systematic compilation of mutations 
found in clinical isolates of drug-
resistant TB. The database is divided 
into two parts. The first part lists all 
the unique mutations reported in 
drug-resistant TB isolates, as well as 
information on the time period of 
isolate collection, country of origin, 
molecular detection method, resistance 
pattern, and susceptibility testing 
method. Since many of the mutations 
are reported in multiple publications, 
we included only the first report that 
identified a specific mutation. As of 
September 1, 2008, TBDReaMDB 
contains 946 unique mutations 
associated with seven different drug 
classes and spread over 36 genes, two 
intergenic/promoter regions, and one 
ribosomal RNA coding region.
Frequency of high-confidence 
mutations associated with drug 
resistance in TB. The second part 
of the database provides data on the 
relative frequency of the most common 
mutations associated with resistance to 
specific drugs, as reported in surveys 
from diverse geographical sites. For 
each drug, we extracted data from 
ten high-quality publications that 
reported the frequency of mutations 
associated with resistance to that drug. 
In addition to the information about 
the frequency of specific mutations 
among resistant and sensitive isolates, 
we have also extracted the type of 
article-specific data, including time 
period of isolate collection and country 
of origin. Such frequency data might 
be useful for the design and validation 
of sequence-based diagnostic tools 
to estimate the number of genes or 
mutations needed to develop a sensitive 
and specific assay. These data may also 
serve as a baseline for surveillance of 
geographical and temporal trends in 
the prevalence of specific mutations, as 
well as for research on the implications 
of geographical differences in mutation 
frequencies for development of new 
diagnostic tools.
Open Access through an 
Interactive Web Site
We have created an interactive Web 
site that allows users to visualize all 
the specific mutations associated 
with resistance to each drug (http://
www.tbdreamdb.com/). For more 
information on the TBDReaMDB Web 
site, please see Box 1. We envision that 
this Web site, in addition to presenting 
the literature in a manually curated 
database, also will serve as a gateway 
to post data from future research 
and development undertaken by its 
users. In keeping with the scientific 
philosophy of open access to the 
public, the database is open to the 
public and free under the Creative 
Commons Attribution 3.0 Unported 
License (http://creativecommons.
org/licenses/by/3.0/). We hope 
that the Web site will be a portal to 
communicate future research on drug 
resistance mechanisms, and to spur 
development of novel rapid diagnostic 
tools and drug discovery. 
Future Directions
The current version of TBDReaMDB, 
as of September 1, 2008, is based on 
literature available up to January 2008. 
The database will be kept updated 
and manually curated to provide 
an accurate picture of the current 
distribution of mutations associated 
with drug resistance in TB. To maintain 
the database up to date, we will 
include new information submitted 
to the mutations lists and mutation 
prevalence data sets.
Submission of new mutations or 
frequency data. We will include novel 
mutations found in clinical isolates 
of drug-resistant TB if they (1) are 
from published studies of clinical 
M. tuberculosis isolates, (2) occur in 
isolates that have been characterized by 
phenotypic drug sensitivity testing, and 
(3) are identified by specification of 
the gene, nucleotide position, and the 
nucleotide and/or amino acid change. 
Mutations that meet these criteria may 
be submitted through the Web site and 
will be added continuously after review.
For studies to be included in the 
database describing the frequency of 
common mutations associated with 
drug resistance in M. tuberculosis,
they must (1) be studies of clinical 
M. tuberculosis isolates; (2) have 
large sample sizes (a minimum of 
100 resistant isolates are required 
for isoniazid and rifampicin; for the 
other drugs sample sizes have been 
determined empirically depending 
on the ten largest studies published 
so far—see Web site); (3) report on 
phenotypic drug sensitivity testing for 
all isolates; (4) use validated methods 
to identify drug resistance mutations; 
(5) identify the nucleotide position and 
the nucleotide change; and (6) specify 
the number of resistant and sensitive 
isolates carrying a specific mutation. 
The frequency database will be updated 
regularly with the most recent data.
Posting of results from future 
applications for open access. We will 
customize the Web site to house results 
and references from projects using 
the information available through our 
resource. Scientists who wish to post 
data on the Web site may submit an 
inquiry for space to present results 
from data analysis, graphics, or links 
to their own Web site or published 
articles.
Box 1. The TBDReaMDB Web 
Site
The TBDReaMDB Web site (http://
www.tbdreamdb.com/) was launched on 
September 1, 2008. All the data collected 
as part of this study are presented on the 
Web site and accessible to the public. The 
data are free of usage but recognition of 
the data source is required; this article 
should be referred to as well. The Web 
site is organized by drug and presents 
all the information about the mutations 
described in the literature. The mutations 
presented have been color coded to 
highlight the high-confidence mutations 
for which frequency data are available. 
For an example of the interface of the 
Web site, see Figure 1. The data are 
also accessible in the form of global 
Excel and tab-delimited spreadsheets 
for all mutations. The database 
developed through this project has been 
constructed to allow continuous updates 
as additional mutations in clinical TB 
isolates are reported. To submit new 
mutations or to give us feedback you 
may e-mail us at the address found on 
the homepage of the Web site. On the 
Web site you can also find all the criteria 
that must be fulfilled for the mutations to 
be qualified for inclusion in the database.PLoS Medicine  |  www.plosmedicine.org 0135 February 2009  |  Volume 6  |  Issue 2  |  e1000002
Conclusions
This project is meant to equip the 
efforts on research and development 
of novel technologies and approaches 
needed for the global surveillance 
and control of drug-resistant M.
tuberculosis, as well as for the diagnosis 
and clinical care of individual 
patients with this disease. We have 
assembled a comprehensive database 
of putative and well-established 
resistance mutations and presented the 
relative frequency and geographical 
distribution of the most common high-
confidence mutations. TBDReaMDB 
is currently the largest and only 
open-access database for mutations 
associated with drug-resistant TB. 
The most important aspect of this 
project is that all the data are readily 
available for open access through a 
publicly accessible Web site. These 
data constitute an important resource 
for the TB research community and 
others to spur further research on drug 
resistance mechanisms that eventually 
may lead to the development of novel 
diagnostic tools and therapeutics to 
combat resistant TB. 
Supporting Information
Text S1.
Systematic Literature Review: Methods
Found at doi:10.1371/journal.
pmed.1000002.sd001 (48 KB DOC).
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